XOMA Corporation (XOMA) News
Filter XOMA News Items
XOMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XOMA News Highlights
- For XOMA, its 30 day story count is now at 2.
- Over the past 1 day, the trend for XOMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about XOMA are DEC and OWL.
Latest XOMA News From Around the Web
Below are the latest news stories about XOMA CORP that investors may wish to consider to help them evaluate XOMA as an investment opportunity.
XOMA Declares Quarterly Preferred Stock DividendsEMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B |
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesLow-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recour |
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueReceived $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent |
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has grant |
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gainThe main point of investing for the long term is to make money. But more than that, you probably want to see it rise... |
XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceEMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET. The conference is being held in New York, NY. The presentation can be accessed at https://bit.ly/3qJMUgT or by visiting the investor relations section of the company’s website at www.xoma.co |
10 Stocks That Are About To ExplodeIn this piece, we will take a look at ten stocks that are about to explode. If you want to skip our background of the stock market then take a look at 5 Stocks That Are About To Explode. The stock market has been quite tumultuous recently. The Federal Reserve’s rapid interest rate hikes that […] |
Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA),Key Insights Significantly high institutional ownership implies XOMA's stock price is sensitive to their trading... |
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyCompleted two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Application in third quarter of 2023 EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent |
XOMA Added to the Russell 2000® and Russell 3000® IndexesEMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000® and Russell 3000® Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Each year, the Russell indexes are reconstituted to capture the 4,0 |